Supplementary Figure 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Eric S. Christenson; Won Jin Ho; Daniel Shu; Jennifer N. Durham; Madelena Brancati; Heather Davis Bruning; Susan Petrie; Hao Wang; Jiayun Lu; Katherine M. Bever; Daniel A. Laheru; Ana De Jesus‐Acosta; Ilene Browner; Ross C. Donehower; Michael J. Pishvaian; Nilofer S. Azad; Qingfeng Zhu; Alens Valentin; Jayalaxmi Suresh Babu; Alexei Hernandez; George Apostol; Yiyang Gao; Nicolás J. Llosa; Franck Housseau; Drew M. Pardoll; Elizabeth M. Jaffee; Robert A. Anders; Dung T. Le

doi:10.1158/1078-0432.29760376

Key Points

Nivolumab and relatlimab target mismatch repair–proficient colorectal cancer for treatment enhancement.
Significant findings indicate improved outcomes in unresectable and metastatic cases with these therapies.
The study utilized IMC analysis to evaluate the tumor microenvironment (TME) and its response to treatment.
Insights from this research may inform future therapeutic strategies for advanced colorectal cancer patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Analysis reveals the effects of nivolumab and relatlimab on treatment outcomes in patients with advanced colorectal cancer, suggesting new therapeutic avenues.

Abstract

Supplementary Figure 4. IMC analysis of TME.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Christenson et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d020a https://doi.org/10.1158/1078-0432.29760376

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading